Innov8Search

Join us live tomorrow as Tara Sharma sits down with Tony Pelle- Managing Director of Medacta Australia Pty Ltd. Tony talks about: - Going from nurse, to sales rep, to MD of a company he helped build from three people to 150+ - The phone call at 34 that put him in charge - and the self-doubt that came with it - Why cultural fit beats skillset every time - The philosophy he's diffused through the whole business: get the right people in the room and watch the magic happen - Why patience, not title-chasing, is the most underrated career move there is Watch live on Tara Sharma's profile: 29 July 2026, 12PM AEDT

A common pattern in senior hiring across ANZ Life Sciences right now:   Searches that stall because the profile doesn't exist in the market. Or it exists, but not at the budget available.   This shows up more often than expected.   Briefs call for a combination of clinical depth, commercial experience, and strategic leadership, often within a specific therapeutic area. The search runs for months. The talent pool turns out to be limited. MTAA research confirms 64% of Australian MedTech companies find it difficult to source local talent for certain positions. The few candidates who fit aren't available or sit outside the compensation range.   By the time this becomes clear, time has been lost and the process resets.   There's a way to avoid this. Before going to market:   - Validate how many candidates fit the brief. - Benchmark compensation against current market reality, not against where the position sat 18 months ago. - Identify adjacent profiles who can step into the position with the right development plan. This gives leadership teams a clear view of what's achievable before the search begins. It reduces delays, avoids late-stage compromise, and allows decisions to be made earlier.   If you're planning a senior hire and want to understand what the market can support: tara@innov8search.com

Tara Sharma just recorded a conversation with Tony Pelle - Managing Director of Medacta Australia Pty Ltd - going live on Wednesday, 29 July 2026 at 12PM AEDT. Tony didn't take the fast track. He trained as a nurse, was drawn into the operating theatre, and followed a friend into orthopaedics. He learned the trade at a small distributor and a global multinational before joining Medacta as the third employee in the country, back in 2008. Eighteen years later, he's grown the business from three people to more than 150 - and helped make a muscle-sparing surgical technique mainstream in Australia. The conversation covers: - Employee #3 to MD: The long, deliberate climb - and the phone call at 34 that changed everything - Get the right people in the room: The simple philosophy behind every team he's built - Cultural fit over CV: Why a bad hire is more expensive than an empty chair - and how he screens for it now - The buck stops here: Making the hard calls, backing your judgement, and why no deal beats a bad deal - Loyalty is more than tenure: What staying - and staying grounded - actually looks like For anyone building a career in MedTech, Pharma or BioTech - wherever you started. Watch live on Tara Sharma's profile: Wednesday, 29 July 2026 at 12PM AEDT.

A consistent theme from MedExec sessions over the past quarter: Executives in ANZ MedTech, MedDevice and Pharma are looking for space to step back and think.   Each month, MedExec brings together leaders across ANZ to review current priorities, upcoming decisions, and how they're approaching them.  The focus stays on what leaders are dealing with right now, not theory.   Recent sessions have covered:   - Retention and engagement across high-performing teams. - Translating global strategy into local execution. - Balancing local decision-making with regional oversight. - Applying AI in day-to-day operations. - Building commercial capability.   Members share openly. What's working, what isn't and what they're testing in their organisations.   Discussions are grounded in real experience, with no commercially confidential or sensitive information shared.  This gives access to perspectives that aren't always available within a single business.   Interest has grown noticeably, with more executives reaching out to join each cohort.   If you're a senior Life Sciences leader in ANZ and would like to learn more about MedExec or upcoming cohorts, you can contact me at tara@innov8search.com or apply via https://lnkd.in/dcjDa9z8

A shift is becoming clear across ANZ and APAC executive hiring in MedTech, MedDevice and Pharma. Organisations aren't just appointing a General Manager / Managing Director. They're appointing someone to move the business forward. Many of these positions involve stepping into underperformance and acting quickly. That includes building credibility with experienced teams, making clear decisions, and balancing hands-on leadership with regional oversight. The cost of getting these appointments wrong has risen sharply. PwC's 2026 Australian healthcare outlook noted that pharmaceutical and MedTech sectors are facing simultaneous pressures: an ageing population driving demand, US tariff uncertainty reshaping global pricing, and the need to build resilience into R&D, supply chain and commercial strategies. In candidate conversations, the strongest operators focus on how they've handled similar situations. They talk through how they diagnosed issues, built trust with established teams, and decided when to step in directly. These mandates come with complexity from day one. The expectation is clear. Deliver growth and move the business forward. The question for organisations: Are you hiring someone to run the business, or someone to change its direction?

Most ANZ MedTech and Pharma boards have a succession plan. Most of those plans haven't been stress-tested against the external market in 18 months.   Research from Russell Reynolds' Global Leadership Monitor H1 2025 of more than 3,000 senior leaders globally found that just 35% feel prepared to address key talent and skills gaps. That's the lowest level since the survey began. 60% cite lack of internal AI expertise as the biggest barrier to organisational capability.   Research from the HR Policy Association and the University of South Carolina's Center for Executive Succession found that stronger CHRO involvement in succession planning correlates with stronger outcomes, and that boards with solid succession practices reported significantly higher CHRO engagement.   In our experience working with ANZ MedTech, MedDevice and Pharma boards, succession plans tend to break in three places:   - Internal successors who haven't built credibility outside their function. They're known to the board, but they're not visible in the broader market when external benchmarks matter. - Plans built for the position as it was, not as it's becoming. The General Manager spec from 2023 doesn't fully describe what the position will need to do in 2027. - External pipelines that were never built. When a sudden departure happens, the search starts cold instead of warm. The boards getting this right are doing three things: - Reviewing succession plans annually against external market reality, not just internal readiness. - Investing in visible market presence for high-potential internal successors. - Maintaining warm relationships with 5-7 external candidates per critical position, before the seat opens. For boards reviewing 2026 succession planning, the question worth asking: Has our plan been tested against the external market this year, or only against ourselves?

What senior Life Sciences leaders are looking for in their next move has shifted in 2026. Most senior executives in MedTech, MedDevice and Pharma aren't actively applying for positions. They're assessing whether a move is worth making. In recent conversations with senior candidates across ANZ, three things come up consistently: Scope beyond a defined remit. They want positions where they can shape strategy, not just execute it. Ownership of complex outcomes. The positions that attract them have measurable impact tied directly to commercial performance. Exposure to higher-level decision-making. They want to be in the room where strategy is made, not where it's communicated. The stability point matters more than most CEOs and CHROs realise. Randstad's 2026 Workplace Insights research found that 50% of Australian talent say work-life balance is the primary reason they stay in their current position. For senior leaders specifically, the calculation isn't just whether the new position pays more. It's whether the move is meaningful enough to disrupt what's already working. Workday's 2026 research highlighted that more than half (57%) of Australians have been in their current position for less than five years, with high performers motivated by growth rather than promotions alone. Senior leaders aren't moving for incremental change. They're moving for substantive change. For CEOs and CHROs running senior searches, this matters in a specific way. If your position description reads as a list of responsibilities rather than a meaningful problem to solve, you'll lose strong candidates early. The strongest organisations we work with reframe their senior positions around the strategic problem the leader will own, not the function they will manage. If you're hiring at this level and want a clearer view of what's resonating in the market, reach out to tara@innov8search.com

What separates ANZ leadership teams that retain executives from those that don't isn't always what happens during the hire but what happens in the first 12 months after. DDI's Global Leadership Forecast 2025 found that high-potential talent is 3.7 times more likely to leave in the next year if their manager doesn't regularly provide opportunities for growth and development.  Trust in immediate managers has dropped to just 29%, a 37% decline since 2022.   In our work with ANZ MedTech, MedDevice and Pharma teams across senior commercial searches, three patterns separate the teams retaining their executives from the teams losing them:   They review the hire decision honestly, even when it goes well. The strong teams ask what they got right, what they got wrong, and what they'd change for the next search. The weaker teams move on.   They revisit the brief at month 3, 6 and 12. The position they hired for in January isn't always the position they need by July. Strong teams have explicit conversations about what's shifted.   They address leadership team friction directly.  When peers aren't aligned, when decision rights are unclear, when meetings aren't producing decisions, the strong teams name it. The weaker teams hope it resolves itself. This last point matters most. When a senior hire doesn't work out in year 2, the cause is rarely the individual. It's usually the team they joined. For CEOs and CHROs reviewing recent senior hires:   What did we get wrong in the brief? What does that say about how we operate as a leadership team?

Just a quick reminder that our 2026 ANZ MedTech Candidate Research Survey is still open. Link to complete in the comments below. If you have already completed it, thank you so much for your contribution, it is genuinely appreciated. Your input will help shape attraction and retention strategies in the MedTech industry and is completely anonymised. If you have not yet had a chance, we would love to hear from you. It takes less than 15 minutes to complete and covers what motivates you, attracts you to a company and makes you stay. Everyone who completes it will receive a complimentary copy of the full report and be entered into a draw to win one of three prizes: - A luxury spa voucher - A voucher to your favourite restaurant - 12 months access to our Innov8Search Personal Branding course and a 1:1 session with Tara Sharma to help you boost your online brand visibility.

If you’re a leader in MedTech and want to better understand what your people actually want from you and what pushes them away, this session is for you. The talent market has shifted. Top performers are no longer staying purely for salary, title or product portfolio. Leadership, culture, flexibility, development and purpose are now playing a much bigger role in attraction and retention. In this session, we’ll unpack: ✔️ What top talent actually wants in 2026 ✔️ Why people leave even when they’re paid well ✔️ How leadership brand impacts retention ✔️ The difference between active versus passive candidates ✔️ Retention strategies that genuinely move the needle The insights are drawn directly from our 2026 ANZ MedTech Candidate Research Survey and real conversations with candidates across sales, clinical, marketing, operations and executive leadership positions. If you lead teams in MedTech, Pharma, register for this event. We’d love to see you there.